Skip to main content
Equibles
PODD logo

PODD · Insulet Corp

Track PODD — free

Use PODD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PODD

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$143.34 -3.10 (-2.12%) At close · Aug 14
Market Cap
$10.06B
Shares
69.35M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$143.34 Open$146.98 Day$143.02–147.17 52W close$133.26–352.82 Avg vol 30d1.6M Short int3.8M · 5.5% float · 3.0d Short vol65% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −36%
      below
      Price vs 50-day avg −8%
      below
      RSI (14) 40
      neutral
      MACD trend Negative
      52-week position 5%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return −13%
      trailing
      6-month return −43%
      trailing
      YTD return −50%
      this year
      Relative strength −56%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $155 › 200d $223 — 200d above 50d
      Institutional flow Distributing
      -11% holders QoQ · +84 funds added
      Insider flow Accumulating
      Net +$838.0K over 90 days · 33% sells
      Short interest Falling
      5.53% of float · ▼ -17.4% MoM · 3.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      707 holders — mid 3-yr range
      Squeeze score 57
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +31%
      Y/Y
      Gross margin 72%
      expanding
      EPS growth −40%
      Y/Y
      Free cash flow $377.7M
      Valuation P/E 27.2
      below peers
      Buyback $475.0M
      authorized
      Balance sheet $485.5M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 44%
      annualized · 1-yr
      Max drawdown −62%
      past year
      ATR 5.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 5, 2026
      Q3 2026
      U.S. Omnipod 14% – 16%
      International Omnipod 28% – 30%
      Total Omnipod 18% – 20%
      Total 17.5% – 19.5%
      Drug Delivery at least -20%
      FY 2026
      U.S. Omnipod 17% – 19%
      Total 20% – 22%
      Total Omnipod 21% – 23%
      International Omnipod 30% – 32%
      Drug Delivery at least -40%
      Adjusted EPS Growth Non-GAAP at least 30%
      Prior guidance period ended · from the 8-K filed May 6, 2026
      U.S. Omnipod · Q2 2026 18% – 20%
      International Omnipod · Q2 2026 28% – 30%
      Total Omnipod · Q2 2026 21% – 23%
      Total · Q2 2026 20% – 22%
      Guided vs delivered · last 1 settled
      Total company revenue high end of our 2024 guidance range
      guided $2B
      $2.07B Beat +3.6%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 2 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −36% Bearish
      Price vs 50-day avg
      −8% Bearish
      RSI (14)
      40 Neutral
      MACD trend
      Negative Bearish
      52-week position
      5% Bearish
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $155 › 200d $223 — 200d above 50d
      Institutional flow Distributing
      -11% holders QoQ · +84 funds added
      Insider flow Accumulating
      Net +$838.0K over 90 days · 33% sells
      Short interest Falling
      5.53% of float · ▼ -17.4% MoM · 3.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      707 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $133 Now $143 · 5% Range high $353
      vs 200-day avg -36% vs 50-day avg -8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted diluted earnings per share non-GAAP $1.66 Three Months Ended June 30, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP Operating Income 129.7M
      +25M Voluntary MDCs and related costs
      -0.2M CFO transition costs
      = Adjusted Operating Income 154.5M
      Adjusted EBITDA non-GAAP $181.7M Three Months Ended March 31, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP Net income 91.1M
      +9.8M Interest expense, net
      +21.9M Income tax expense
      +26.2M Depreciation and amortization
      +21.3M Stock-based compensation expense
      +11.7M Voluntary medical device correction
      -0.3M CFO transition
      = Adjusted EBITDA 181.7M
      Adjusted net income non-GAAP $354.4M Full Year 2025 —
      GAAP → non-GAAP reconciliation
      GAAP Net income $247.1M
      -$2.7M CEO and CFO transition costs
      +$5.8M Loss on investments
      +$123.1M Loss on extinguishment of debt
      -$12.3M Gain on derivative asset
      -$6.5M Tax matters
      = Adjusted net income $354.4M
      Estimated active Omnipod users globally 600,000 as of December 31, 2025 —
      Free cash flow non-GAAP $377.7M Full Year 2025 —
      GAAP → non-GAAP reconciliation
      GAAP Net cash provided by operating activities $569.3M
      -$191.6M Capital expenditures
      = Free cash flow $377.7M

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PODD
      Insulet Corp
      this stock
      		$10.06B -49.6% +30.7% 27.2 5.5%
      ABT
      Abbott Laboratories
      		 $194.07B -11.2% +5.7% 31.2 1.3%
      SYK
      Stryker Corp
      		 $133.18B -3.5% +11.2% 36.0 2.2%
      MDT
      Medtronic plc
      		 $116.83B -5.0% +8.4% 24.5 1.4%
      BSX
      Boston Scientific Corp
      		 $75.11B -45.6% +12.5% 21.0 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      707
      % held
      102.8%
      Net QoQ
      +1.5M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,003
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      3.8M
      Days to cover
      3.0d
      Change
      -809.5K sh
      View
      Short Volume
      Short vol %
      65%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      67
      Value
      $10.6K
      As of
      Jul 10, 2026
      View
      Off-Exchange
      Off-exchange %
      40.2%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$838.0K
      Buyers / Sellers
      2 / 1
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Tina Smith
      Amount
      $100.0K–$250.0K
      Traded
      May 7, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $2.7B
      Net income (FY)
      $247.1M
      EPS diluted
      $3.48
      View
      Buybacks
      Authorized · 2 programs
      $475.0M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 5, 2026
      This year
      16
      View
      Proposed Sales
      Value
      $59.9K
      Shares
      418
      Filed
      Jun 3, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View
      Investor Relations
      Latest news
      Insulet Reports Second Quarter 20…
      Published
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PODD +1.5% -12.6% -42.5% -13.3% -49.6%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +1.1% -17.1% -56.3% -17.2% -63.4%

      Capital returns

      Buyback programs · 2 active · as of Feb 28, 2026
      Authorized (total)
      $475.00M
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1145197 CUSIP 45784P101 13F (30d) 683 filings 650 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)